Compare Stocks → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:LBPHNASDAQ:OPNTNASDAQ:TRVINYSE:VHAQ Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLBPHLongboard Pharmaceuticals$21.99+1.3%$19.96$3.60▼$28.15$792.08M1.251.17 million shs139,384 shsOPNTOpiant Pharmaceuticals$20.58$7.34▼$29.25$108.83M0.8477,920 shs562,700 shsTRVITrevi Therapeutics$2.92+10.6%$3.03$0.97▼$4.00$205.66M0.91258,566 shs259,174 shsVHAQViveon Health Acquisition$10.00$8.27$0.00▼$12.48$66.49M-0.12150 shsN/ABeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLBPHLongboard Pharmaceuticals+1.34%-3.59%+18.35%+11.34%+118.81%OPNTOpiant Pharmaceuticals0.00%0.00%0.00%0.00%0.00%TRVITrevi Therapeutics+10.61%-2.99%+1.39%+78.05%+0.69%VHAQViveon Health Acquisition0.00%0.00%+11.11%-12.89%-9.09%The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLBPHLongboard Pharmaceuticals2.5214 of 5 stars4.52.00.00.01.91.70.0OPNTOpiant PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATRVITrevi Therapeutics2.7454 of 5 stars3.55.00.00.00.93.30.0VHAQViveon Health AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLBPHLongboard Pharmaceuticals3.00Buy$43.6798.58% UpsideOPNTOpiant PharmaceuticalsN/AN/AN/AN/ATRVITrevi Therapeutics3.00Buy$8.50191.10% UpsideVHAQViveon Health AcquisitionN/AN/AN/AN/ACurrent Analyst RatingsLatest TRVI, LBPH, VHAQ, and OPNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/7/2024LBPHLongboard PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.005/3/2024LBPHLongboard PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$60.005/3/2024LBPHLongboard PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$32.00 ➝ $34.005/1/2024LBPHLongboard PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$36.004/16/2024LBPHLongboard PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.004/10/2024LBPHLongboard PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$60.004/9/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/21/2024TRVITrevi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.003/21/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/15/2024LBPHLongboard PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLBPHLongboard PharmaceuticalsN/AN/AN/AN/A$1.67 per shareN/AOPNTOpiant Pharmaceuticals$47.78M0.00N/A24.75$9.92 per share0.00TRVITrevi TherapeuticsN/AN/AN/AN/A$1.29 per shareN/AVHAQViveon Health AcquisitionN/AN/AN/AN/A($3.22) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLBPHLongboard Pharmaceuticals-$54.42M-$2.24N/AN/AN/AN/A-49.87%-46.04%8/1/2024 (Estimated)OPNTOpiant Pharmaceuticals$3.01M-$6.56N/AN/AN/A-147.90%-97.03%-59.66%N/ATRVITrevi Therapeutics-$29.07M-$0.29N/AN/AN/AN/A-31.51%-28.89%8/8/2024 (Estimated)VHAQViveon Health Acquisition-$610KN/A0.00∞N/AN/AN/AN/AN/ALatest TRVI, LBPH, VHAQ, and OPNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024Q4 2023TRVITrevi Therapeutics-$0.10-$0.08+$0.02-$0.08N/AN/A3/12/2024Q4 2023LBPHLongboard Pharmaceuticals-$0.60-$0.62-$0.02-$0.62N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLBPHLongboard PharmaceuticalsN/AN/AN/AN/AN/AOPNTOpiant PharmaceuticalsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/AVHAQViveon Health AcquisitionN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLBPHLongboard PharmaceuticalsN/A31.4331.43OPNTOpiant Pharmaceuticals0.605.485.48TRVITrevi TherapeuticsN/A15.0315.03VHAQViveon Health AcquisitionN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipLBPHLongboard Pharmaceuticals63.28%OPNTOpiant Pharmaceuticals42.39%TRVITrevi Therapeutics95.76%VHAQViveon Health Acquisition22.14%Insider OwnershipCompanyInsider OwnershipLBPHLongboard Pharmaceuticals4.64%OPNTOpiant Pharmaceuticals25.15%TRVITrevi Therapeutics27.46%VHAQViveon Health Acquisition75.27%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableLBPHLongboard Pharmaceuticals5036.02 million34.35 millionOptionableOPNTOpiant Pharmaceuticals375.27 million3.87 millionNot OptionableTRVITrevi Therapeutics2570.43 million51.09 millionOptionableVHAQViveon Health AcquisitionN/A6.65 million1.64 millionNot OptionableTRVI, LBPH, VHAQ, and OPNT HeadlinesSourceHeadlineClearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success - Updatedfinance.yahoo.com - May 3 at 10:28 AMClearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Successfinance.yahoo.com - May 2 at 3:36 PMViveon Health Acquisition Corp.: Viveon Healthcare Acquisition Corp. Confirms Commitment To Proceed With Business Combination Processfinanznachrichten.de - February 28 at 3:42 PMVIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESSglobenewswire.com - February 27 at 4:45 PMNYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ)finance.yahoo.com - February 21 at 7:40 PMViveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSEfinance.yahoo.com - December 27 at 7:32 PMNYSE American to Commence Delisting Proceedings Against Viveon Health Acquisition Corp. (VHAQ)tmcnet.com - December 22 at 6:29 PMSan Antonio, Texas Clearday (CLRD-OTCQX) is proud to honor our US Veterans through the Company’s Clearday Club in San Antonio, Texas.finance.yahoo.com - November 13 at 8:17 PMNYSE American to Commence Delisting Proceedings with Respect to the Warrants of Viveon Health Acquisition Corp. (VHAQ.WS)finance.yahoo.com - October 24 at 12:34 PMVHAQ-R Viveon Health Acquisition Corp.seekingalpha.com - September 23 at 7:56 AMViveon Health Acquisition Received Audit Opinion With Going Concern Explanationmarketwatch.com - September 15 at 6:11 PMVIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATIONfinance.yahoo.com - September 15 at 6:11 PMViveon Healthcare Increases Consideration Offered to Clearday Shareholdersfinance.yahoo.com - September 5 at 6:45 PMSPAC Viveon ups merger consideration for Clearday to $500Mmsn.com - August 29 at 4:18 PMViveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger Agreementfinance.yahoo.com - August 29 at 4:18 PMVIVEON HEALTH ACQUISITION CORP. RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-K FILINGfinance.yahoo.com - April 25 at 9:05 PMViveon Health Acquisition Corp. (VHAQ-RT)finance.yahoo.com - April 18 at 3:32 PM(Updated) Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to Marketfinance.yahoo.com - April 12 at 12:15 PMSPAC Viveon to merge with senior-care tech provider Cleardayseekingalpha.com - April 6 at 1:59 PMSPAC Viveon signs merger LOI with health monitoring platform Cleardaymsn.com - March 1 at 2:48 PMViveon Health Acquisition Corp. and Clearday Inc. Announce Signed Letter of Intent to Merge and Create a Leading Longevity Care Companyfinance.yahoo.com - March 1 at 9:48 AMSPAC Viveon terminates planned merger with Suneva Medicalmsn.com - February 6 at 6:48 PMViveon Health Acquisition Corp. Announces Termination of Merger Agreement with Suneva Medical, Inc.finance.yahoo.com - February 3 at 12:53 PMVIVEON HEALTH ACQUISITION CORP. Announces Adjournment of Special Meeting in Connection with ...kentuckytoday.com - January 27 at 10:07 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsLongboard PharmaceuticalsNASDAQ:LBPHLongboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.Opiant PharmaceuticalsNASDAQ:OPNTOpiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.Trevi TherapeuticsNASDAQ:TRVITrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.Viveon Health AcquisitionNYSE:VHAQViveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.